Recombinant sCD40L (Toralizumab Biosimilar) 抗体
适用: 人
BR, IF
宿主: 小鼠
Chimeric
IDEC-131
unconjugated
Recombinant Antibody
-
- 抗原 See all sCD40L (Toralizumab Biosimilar) products
- sCD40L (Toralizumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- Chimeric
-
标记
- This sCD40L (Toralizumab Biosimilar) antibody is un-conjugated
- 应用范围
- Blocking Reagent (BR), Immunofluorescence (IF)
- 原理
- Anti-CD154 [IDEC-131 (Toralizumab)], Mouse IgG1, kappa
- 特异性
- This antibody is a non agonistic antibody specifc for human CD40 ligand.
- 产品特性
-
Original Species of Ab: Mouse
Original Format of Ab: IgG1
- 纯化方法
- Protein A affinity purified
- 免疫原
- The original monoclonal antibody was generated by immunization with a soluble fusion protein of human gp39 (gp39-CD8).
- 克隆位点
- IDEC-131
- 亚型
- IgG1 kappa
-
anti-sCD40L (Toralizumab Biosimilar) antibody
适用: 人 BR, IF 宿主: 兔 Chimeric IDEC-131 unconjugated Recombinant Antibody
-
- 应用备注
- This antibody binds CD154 with an binding affinity of Kd = 5.6 nM for theoriginally characterized antibody (Brams et al., 2001)/ Phase I clinical trials of the antibody in pateints with systemic lupus ezythematoses revealed that a single intravenous infusion at doses of 0.05-15.0 mg/kg is safe and well tolerated in patients. (Davis et al., 2001). Although, no further development for this indication has been reported since the disclosure of disappointing phase II results in April 2000. In January 2001, phase II trials in psoriasis and idiopathic thrombocytopenic purpura (ITP) were initiated. By january 2002, a phase II trial in Crohn's disease was also ongoing. (Dumont FJ, 2002) Ab IDEC-131 was tested alone and in combination with rapamycin and DST for its ability to inhibit rhesus MLRs and it was seen that therapy with IDEC-131, rapamycin, and DST induced long-term allograft survival without intermittent acute rejection.(He Xu et, al., 2003) IDEC-131 was also used in a comparative study using 3 monoclonal antibodies αCD40 (2C10R4) and αCD154 (5C8H1 and IDEC-131 to check CD40/CD154 T cell costimulation pathway in a non-human primate cardiac allotransplant model (O'Neill et al., 2017) Other suitable use in ELISA, FC, IF, IP.
- 说明
-
This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- 限制
- 仅限研究用
-
- 浓度
- 1 mg/mL
- 缓冲液
- PBS with 0.02 % Proclin 300.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- 抗原
- sCD40L (Toralizumab Biosimilar)
- Abstract
- sCD40L (Toralizumab Biosimilar) 产品
- 物质类
- Biosimilar
- 背景
- CD40L, gp39, TRAP, Tumor necrosis factor ligand superfamily member 5, TNFSF5, T-cell antigen Gp39, TNF-related activation protein, TNF-related activation protein
- UniProt
- P29965
-
You are here:
